A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial
Authors
Kulke, MRuszniewski, P
van Cutsem, E
Valle, Juan W
de Herder, W
Pavel, M
Degtyarev, E
Lam, D
Salazar, R
Borbath, I
Fazio, N
Lombard-Bohas, C
Yao, J
Affiliation
Dana-Farber Cancer Institute, Boston, USAIssue Date
2015